First Turn Management LLC Sells 61,476 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

First Turn Management LLC lessened its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 16.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 318,327 shares of the company's stock after selling 61,476 shares during the quarter. Apogee Therapeutics comprises about 2.0% of First Turn Management LLC's investment portfolio, making the stock its 27th largest position. First Turn Management LLC owned approximately 0.54% of Apogee Therapeutics worth $12,526,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in APGE. American Century Companies Inc. boosted its stake in Apogee Therapeutics by 34.0% in the second quarter. American Century Companies Inc. now owns 8,673 shares of the company's stock valued at $341,000 after acquiring an additional 2,199 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Apogee Therapeutics in the 2nd quarter worth $272,000. Arizona State Retirement System boosted its position in shares of Apogee Therapeutics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company's stock worth $236,000 after purchasing an additional 258 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Apogee Therapeutics by 56.8% during the second quarter. Victory Capital Management Inc. now owns 156,266 shares of the company's stock worth $6,149,000 after purchasing an additional 56,607 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in Apogee Therapeutics by 26.3% in the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company's stock valued at $253,000 after purchasing an additional 1,340 shares during the last quarter. Institutional investors own 79.04% of the company's stock.

Insiders Place Their Bets

In related news, CFO Jane Henderson sold 6,000 shares of the business's stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $48.26, for a total value of $289,560.00. Following the completion of the transaction, the chief financial officer now directly owns 200,871 shares in the company, valued at approximately $9,694,034.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of the company's stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $37.26, for a total transaction of $558,900.00. Following the completion of the transaction, the chief executive officer now owns 1,474,487 shares of the company's stock, valued at approximately $54,939,385.62. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Jane Henderson sold 6,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $48.26, for a total transaction of $289,560.00. Following the transaction, the chief financial officer now owns 200,871 shares of the company's stock, valued at $9,694,034.46. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 120,995 shares of company stock worth $5,218,774. Corporate insiders own 36.10% of the company's stock.

Apogee Therapeutics Stock Performance

NASDAQ:APGE traded up $2.19 during mid-day trading on Friday, hitting $51.38. The company had a trading volume of 539,239 shares, compared to its average volume of 515,230. Apogee Therapeutics, Inc. has a fifty-two week low of $14.19 and a fifty-two week high of $72.29. The firm has a market cap of $2.31 billion, a P/E ratio of -9.79 and a beta of 2.74. The business's fifty day moving average is $46.97 and its two-hundred day moving average is $49.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). Equities analysts forecast that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.